EPIC Program Annual Data Tables 2005-2006: Table VII
| Therapeutic Class** | Number of Claims |
Percent of Claims |
EPIC Payments |
Number of Participants |
|---|---|---|---|---|
| Total*** | 4,775,144 | 41.46% | $330,656,167 | |
| BETA-ADRENERGIC BLOCKING AGENT | 920,498 | 7.99% | $27,873,095 | 169,592 |
| HMG-COA REDUCTASE INHIBITORS | 694,797 | 6.03% | $97,333,548 | 159,412 |
| ANGIOTENSIN-CONVERTING ENZYME | 572,103 | 4.97% | $19,923,456 | 112,460 |
| PROTON-PUMP INHIBITORS | 415,867 | 3.61% | $78,230,749 | 100,617 |
| DIHYDROPYRIDINES | 393,136 | 3.41% | $29,525,356 | 81,323 |
| ANTIDEPRESSANTS | 386,759 | 3.36% | $27,471,336 | 74,306 |
| ANGIOTENSIN II RECEPTOR ANTAGO | 369,125 | 3.20% | $29,651,508 | 78,518 |
| OPIATE AGONISTS | 354,260 | 3.08% | $13,914,074 | 93,487 |
| LOOP DIURETICS | 338,409 | 2.94% | $2,152,898 | 76,808 |
| THYROID AGENTS | 330,190 | 2.87% | $4,580,147 | 64,287 |
* Table VII provides the percent of adjudicated claims for the program year (October 1, 2005 through September 30, 2006) as they fall into particular categories of Therapeutic Class.
** American Hospital Formulary Service® (AHFS) Pharmacologic-Therapeutic Classification.
*** This report contains the top ten drug classes; additional drug classes comprise the remainder of claims up to 100.00%.
